Clinical trial
Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis…
NCT00429754 · Radboud University Medical Center, Other · Withdrawn
Key facts
| NCT number | NCT00429754 |
|---|---|
| Title | Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP) |
| Official title | A Pharmacokinetic Evaluation of the Addition of Aprepitant to the Bleomycin -Etoposide - Cisplatin (BEP) Treatment of Patients With Testis Carcinoma (A-BEP) |
| Lead sponsor | Radboud University Medical Center, Other |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Withdrawn |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Nausea, Vomiting |
| Intervention type | Drug |
| Interventions | Aprepitant |
| Enrollment | 0 |
| Completion | Sep 1, 2008 |
| First posted | Feb 1, 2007 |
| Last update posted | Jan 26, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: